Professor, Oncology, Mayo Medical School
Oncology
Dr. Axel F. Grothey, MD
|
|
Give Review
Axel Grothey is an expert in the field of Oncology. Dr. Axel F. Grothey is a published doctor and has 102 publications published. The lastest was: '[Use of alternative medicine in oncology patients].' He is registered with Medicare.
Publications
- MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
- Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
- Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting OVerall Survival.
- Title: Regorafenib in the treatment of colorectal cancer.
- Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
- Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
- Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.
- ACCENT-Based Web Calculators to Predict Recurrence and OVerall Survival in Stage III Colon Cancer.
- Individual Patient Data Analysis of Progression-Free Survival Versus OVerall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized T...
- Bevacizumab exposure beyond first Disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
- Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care.
- Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
- Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin(®) Registry - Investigation of Effectiveness and Saf...
- The challenge to optimize medical therapy for advanced colorectal cancer.
- UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
- Adolescent and young adult colorectal cancer.
- Disease-free survival in colon cancer: still relevant after all these years!
- Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement.
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
- VEGF inhibition beyond tumour progression.
- Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.
- S-1 in colorectal cancer: a new standard of care?
- A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial.
- Highlights in metastatic colorectal cancer from the 2012 american society of clinical oncology annual meeting.
- Regorafenib in metastatic colorectal cancer.
- Antiangiogenic therapy in cancer: a new era has begun.
- Clinical trial designs for prospective validation of biomarkers.
- N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.
- Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized t...
- Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
- OVerall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or...
- Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
- First- and second-line therapy of metastatic colorectal cancer.
- Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
- Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
- Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.
- Do all patients with metastatic colorectal cancer need chemotherapy until Disease progression?
- Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
- Is there a third-line therapy for metastatic colorectal cancer?
- The continuum of care: a paradigm for the management of metastatic colorectal cancer.
- Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
- Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.
- Symptom control trials: a 20-year experience.
- Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
- Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO ...
- Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
- Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.
- Sound footing or slippery slope? The value of secondary analyses of randomized trials.
- End points in advanced colon cancer clinical trials: a review and proposal.
- End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials ...
- New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference.
- Biological therapy and other novel therapies in early-stage Disease: are they appropriate?
- Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
- Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
- Surrogate endpoints for oVerall survival in early colorectal cancer from the clinician''s perspective.
- Targeting the right target: epidermal growth factor receptor-directed individualized therapy.
- Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
- Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
- Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
- Chemotherapy-induced Peripheral neuropathy: prevention and treatment strategies.
- New lessons from "old" chemotherapy in colorectal cancer.
- Bevacizumab beyond first progression is associated with prolonged oVerall survival in metastatic colorectal cancer: results from a large observational cohort study (BR...
- North Central Cancer Treatment Group--achievements and perspectives.
- A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer.
- Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
- Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
- Individualizing therapy for metastatic colorectal cancer.
- Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with...
- Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity.
- KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
- Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
- A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for Acute chemotherapy-induced emesis.
- [Mucoraceae mycoses: clinical aspects and pathology in ten patients].
- [Zygomycoses: clinical aspects and pathology in 10 patients].
- Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with Myelodysplastic syndromes. A pha...
- N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization ...
- Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-...
- Re: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line.
- Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
- [Use of alternative medicine in oncology patients].
- The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors.
- Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
- Where do we stand with 5-fluorouracil?
- [Diagnostic and therapeutic management of the superior vena cava syndrome].
- Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
- Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin.
- Cisplatin resistance and oncogenes--a review.
- Breast size as risk factor for tumor size at diagnosis.
- Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer.
- C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines.
- A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats.
- Human hematopoietic growth factors: old lessons and new perspectives.
- Chemotherapy in elderly patients with colorectal cancer.
- New chemotherapy approaches in colorectal cancer.
- Cyclooxygenase-2: a novel target for cancer chemotherapy?
- A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study.
- Chemotherapy for advanced gastric cancer.
- Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
- Current Options for Third-Line Treatment of Metastatic Colorectal Cancer: Discussion.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Coagulation Disorders (incl. Hemophilia)
- Deep Vein Thrombosis (DVT)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
Ruhr- University Bochum Faculty of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1841278678 | |
| NPPES Provider LastName | GROTHEY | |
| NPPES Provider FirstName | AXEL | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 101.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841278678 |
| Last Name Of The Provider | GROTHEY |
| First Name Of The Provider | AXEL |
| View All |
Similar Doctors
|
|
Dr. Kiernan J. Minehan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward T. Creagan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kostandinos Sideras, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Viswanatha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Dingli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil E. Kay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn C. Hartmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evanthia Galanis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|